PuSH - Publication Server of Helmholtz Zentrum München: A novel AMPK inhibitor sensitizes pancreatic cancer cells to ferroptosis induction.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Schneider, C.* ; Hilbert, J.* ; Genevaux, F.* ; Höfer, S.* ; Kraus, L.* ; Schicktanz, F.* ; Contreras, C.T.* ; Jansari, S.* ; Papargyriou, A. ; Richter, T.* ; Alfayomy, A.M.* ; Falcomatà, C.* ; Schneeweis, C.* ; Orben, F.* ; Öllinger, R.* ; Wegwitz, F.* ; Boshnakovska, A.* ; Rehling, P.* ; Müller, D.* ; Ströbel, P.* ; Ellenrieder, V.* ; Conradi, L.* ; Hessmann, E.* ; Ghadimi, M.* ; Grade, M.* ; Wirth, M.* ; Steiger, K.* ; Rad, R.* ; Kuster, B.* ; Sippl, W.* ; Reichert, M.* ; Saur, D.* ; Schneider, G.*

A novel AMPK inhibitor sensitizes pancreatic cancer cells to ferroptosis induction.

Adv. Sci.:e2307695 (2024)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Cancer cells must develop strategies to adapt to the dynamically changing stresses caused by intrinsic or extrinsic processes, or therapeutic agents. Metabolic adaptability is crucial to mitigate such challenges. Considering metabolism as a central node of adaptability, it is focused on an energy sensor, the AMP-activated protein kinase (AMPK). In a subtype of pancreatic ductal adenocarcinoma (PDAC) elevated AMPK expression and phosphorylation is identified. Using drug repurposing that combined screening experiments and chemoproteomic affinity profiling, it is identified and characterized PF-3758309, initially developed as an inhibitor of PAK4, as an AMPK inhibitor. PF-3758309 shows activity in pre-clinical PDAC models, including primary patient-derived organoids. Genetic loss-of-function experiments showed that AMPK limits the induction of ferroptosis, and consequently, PF-3758309 treatment restores the sensitivity toward ferroptosis inducers. The work established a chemical scaffold for the development of specific AMPK-targeting compounds and deciphered the framework for the development of AMPK inhibitor-based combination therapies tailored for PDAC.

Impact Factor

Scopus SNIP

Altmetric

14.300

0.000